Novel Proteasome Inhibitor ACU-D1 Safe, Effective in Patients With Moderate to Severe Rosacea

Topical ACU-D1 is safe and well-tolerated by patients with moderate to severe rosacea and is effective in reducing inflammatory lesions and erythema, according to a recently published article in Journal of Drugs in Dermatology.

Researchers designed a trial to evaluate efficacy and safety of the novel inhibitor of the 26S proteasome, ACU-D1, for the treatment of moderate to severe rosacea. The trial was a 14-week, randomized, double-blinded, placebo-controlled study that randomized 40 adult participants with moderate to severe rosacea to either ACU-D1 or comparator vehicle.

A total of 38 patients completed the study. ACU-D1 reduced inflammatory lesions in 92% of patients and 27% of patients experienced at least a 2-grade reduction in Investigator Global Asssessment to clear to near clear. Erythema was also improved in the active arm.

“This study demonstrates that topical ACU-D1 is safe and well-tolerated by patients in the study and demonstrates efficacy in reducing inflammatory lesions and erythema in patients with rosacea,” concluded the study authors.

Reference
Jackson JM, Coulon R, Arbiser JL. Evaluation of a first-in-class proteasome inhibitor in patients with moderate to severe rosacea. J Drugs Dermatol. 2021;20(6):660-664. doi:10.36849/JDD.2021.5925